Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Express Scripts
Mallinckrodt
Dow
Farmers Insurance
Queensland Health
Deloitte
Harvard Business School
Cipla

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LOPINAVIR; RITONAVIR

« Back to Dashboard

Clinical Trials for Lopinavir; Ritonavir

Trial ID Title Status Sponsor Phase Summary
NCT00004578 ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects Completed Abbott Phase 1/Phase 2 To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
NCT00006144 A Study of HIV-Disease Development in Aging Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
NCT00014937 Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lopinavir; Ritonavir

Condition Name

Condition Name for Lopinavir; Ritonavir
Intervention Trials
HIV Infections 134
HIV 33
HIV Infection 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lopinavir; Ritonavir
Intervention Trials
HIV Infections 187
Acquired Immunodeficiency Syndrome 40
Immunologic Deficiency Syndromes 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lopinavir; Ritonavir

Trials by Country

Trials by Country for Lopinavir; Ritonavir
Location Trials
United States 707
Spain 75
Thailand 61
Canada 54
South Africa 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lopinavir; Ritonavir
Location Trials
California 57
New York 50
Florida 39
Texas 38
Illinois 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lopinavir; Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Lopinavir; Ritonavir
Clinical Trial Phase Trials
Phase 4 80
Phase 3 54
Phase 2/Phase 3 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lopinavir; Ritonavir
Clinical Trial Phase Trials
Completed 182
Terminated 24
Unknown status 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lopinavir; Ritonavir

Sponsor Name

Sponsor Name for Lopinavir; Ritonavir
Sponsor Trials
Abbott 55
National Institute of Allergy and Infectious Diseases (NIAID) 45
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lopinavir; Ritonavir
Sponsor Trials
Other 271
Industry 134
NIH 72
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Merck
Moodys
Express Scripts
Argus Health
Chinese Patent Office
Teva
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.